Related Experiment Video

Updated: Aug 23, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Gefitinib in recurrent glioblastoma

M Raphael Pfeffer, Mark L Levitt, Dan Aderka

    Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
    |July 1, 2004
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
    08:00

    The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

    Published on: April 16, 2019

    PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator
    10:48

    PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator

    Published on: December 28, 2017

    Related Experiment Videos

    Last Updated: Aug 23, 2026

    Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
    06:15

    Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

    Published on: October 27, 2014

    The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
    08:00

    The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

    Published on: April 16, 2019

    PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator
    10:48

    PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator

    Published on: December 28, 2017

    Related Concept Videos

    Treatment Resistent Cancers02:56

    Treatment Resistent Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

    Articles linked to this work by shared authors, journal, and citation graph.

    Individual Participant Data Meta-Analysis (IPDMA) of long-term COVID-19 outcomes in a systematic review-informed, international, multidisciplinary database.

    Health and social care delivery research·2026

    Utilization of tissue-free minimal residual disease testing in colorectal cancer patients from Asia and Middle East.

    Frontiers in oncology·2024

    Effect of Opaganib on Supplemental Oxygen and Mortality in Patients with Severe SARS-CoV-2 Based upon FIO2 Requirements.

    Microorganisms·2024

    Combined Antitumor Effect of the Serine Protease Urokinase Inhibitor Upamostat and the Sphingosine Kinase 2 Inhibitor Opaganib on Cholangiocarcinoma Patient-Derived Xenografts.

    Cancers·2024

    Stereotactic MR-guided on-table adaptive radiation therapy (SMART) for borderline resectable and locally advanced pancreatic cancer: A multi-center, open-label phase 2 study.

    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2023

    Tumor Differentiation as a Prognostic Marker in Clinically Staged T1bN0 Esophageal Adenocarcinoma.

    Cancer investigation·2023

    Perioperative Durvalumab for Resectable Non-Small Cell Lung Cancer: Updated Outcomes From the Phase III AEGEAN Trial.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    Long-Term Survival Outcomes of Modified-FOLFOXIRI Plus Cetuximab Versus Bevacizumab in RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Analysis of the DEEPER Trial.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    Refined Continuous Risk Index for Accurately Predicting Outcomes of Patients With Chronic Lymphocytic Leukemia After Limited-Duration Therapy.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    Medical Therapy for Hormone Receptor-Positive, HER2-Negative Stage I-III Breast Cancer: ASCO Living Guideline, Version 2026.1.0.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    Salvage Hypofractionated Accelerated Versus Standard Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: A Phase III Randomized Clinical Trial.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    The Patient Who Could Not Die.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    Targeting CKIP-1 for Disease Therapy: Cellular Functions, Molecular Networks, and Clinical Potential.

    Cell proliferation·2026

    YTHDC1 Orchestrates Glucose and Glutamate Rewiring to Overcome Lethal Metabolic Stress in Triple-Negative Breast Cancer.

    Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026

    Natural Product Toosendanin Suppresses the Malignant Development of Skin Melanoma by Targeting BNC2 for Degradation.

    Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026

    An Immune-Activated Co-culture Model of Patient-Derived Gastric Cancer Organoids and Peripheral Blood Mononuclear Cells for Personalized Chemotherapy Screening.

    Acta biomaterialia·2026

    Cardio-renal protection of MRAs in kidney-transplanted diabetic patients.

    Pharmacological research·2026

    Substrate-Derived Peptides for Selective Covalent Inhibition of Protein Tyrosine Kinases.

    ACS chemical biology·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us